Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PLPliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc. (PLRX)

NASDAQ Global Select · Currency in USD
$0.86 ▼ 0.00 (-0.20%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.86 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$0.87
Open
$0.88
Day's Range
$0.83 – $0.88
52 Week Range
$0.83 – $1.95
Volume
446,817
Avg. Volume
467,667
Market Cap
$53.48M
Beta (5Y Monthly)
1.28
PE Ratio (TTM)
--
EPS (TTM)
-$1.49
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$25.86

Profile: Pliant Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
49
CEO
Bernard Coulie

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.37
DateEst.Actual
Aug 11, 2026-$0.34-$0.36Miss
May 11, 2026-$0.36-$0.32Beat
Mar 11, 2026-$0.42-$0.35Beat
Nov 6, 2025-$0.53-$0.43Beat
Aug 7, 2025-$0.62-$0.71Miss
May 8, 2025-$0.78-$0.92Miss

Analyst view

Consensus price target
$25.86 ▲ +2,894.4%
Range $2.00 – $48.00
Rating: Buy
Buy 50% · Hold 44% · Sell 6%

Get free alerts on PLRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.